Tumor Development
Tumor Development - Related Videos
09:26
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
0 Views •
Cited by 8 •
2011
Here, we established a method for drug efficacy testing with surgical specimens of brain tumors, termed “tumor explant method”. With this method, we can evaluate drug efficacy without breaking the microenvironment of solid tumors. To validate reliability of this method, we describe representative data with our glioma specimen treated with the current first-line chemotherapeutic agent, temozolomide.
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
0 Views •
Cited by 23 •
2016
Utilizing patient-derived tumors in a subcutaneous preclinical model is an excellent way to study the efficacy of novel therapies, predictive biomarker discovery, and drug resistant pathways. This model, in the drug development process, is essential in determining the fate of many novel anti-cancer therapies prior to clinical investigation.
11:31
Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
0 Views •
Cited by 11 •
2016
We describe a method for the detection of tumor nodule development in the lungs of an adenocarcinoma mouse model using micro-computed tomography and its use for monitoring changes in nodule size over time and in response to treatment. The accuracy of the assessment was confirmed with end-point histological quantification.
08:17
Murine Experimental Model of Original Tumor Development and Peritoneal Metastasis via Orthotopic Inoculation with Ovarian Carcinoma Cells
0 Views •
Cited by 4 •
2016
To clarify the multistep process of peritoneal dissemination of ovarian carcinoma, the current study presents a murine experimental model of original tumor development and peritoneal metastasis via orthotopic inoculation with these tumor cells.
02:43
Tumor Implantation and Injection of a Tumor Vaccine in a Mouse Model
0 Views •
2025
This video demonstrates a cell-based tumor vaccination assay. A mouse, intradermally injected with B16-F10 melanoma cells for tumor formation, is vaccinated with B16-F10 cells secreting Flt3L cytokine near the developed tumor. The secreted Flt3L from the vaccine promotes the maturation and proliferation of dendritic cells that then present tumor antigens to T cells in lymph nodes, triggering a targeted anti-tumor immune response.
FAQs
Successive genetic or epigenetic alterations can affect different controls at different times. Early changes may disrupt cell-cycle regulation, DNA repair, or apoptosis, while later alterations can support tissue invasion, angiogenesis, immune evasion, or metastasis. This stepwise accumulation helps explain why tumors evolve over time and why cells within a tumor may acquire progressively different properties.
Both can disturb regulators of the cell cycle, DNA repair, apoptosis, and communication with neighboring cells. When these controls fail, cells may survive or proliferate abnormally, creating conditions for additional alterations. This combination connects molecular changes to tissue-level behavior and provides multiple points at which researchers can investigate tumor formation.
The key distinction described in this context is behavior: malignant tumors can acquire tissue-invasion and metastatic properties, whereas tumor development may also produce a benign tumor. Researchers therefore examine alterations associated with invasion and spread, not only abnormal growth, when evaluating progression and disease significance.
Alterations affecting communication with neighboring cells can change how abnormal cells interact with tissue. Additional changes may promote angiogenesis, the development of blood-vessel support, and immune evasion, allowing tumor-associated cells to persist in their surroundings. These processes broaden tumor behavior beyond cell-cycle control and help explain progression toward invasion or metastatic disease.
Researchers combine experimental models with genomic analyses to examine how tumors evolve. Models provide a setting for studying changes in cells and tissues, while genomic analyses identify alterations associated with progression. Comparing findings across stages can connect molecular events with abnormal growth, survival, invasion, or other properties, supporting interpretation of tumor evolution rather than a single-time snapshot.
This research can identify cancer risk factors, biomarkers, and therapeutic targets. It also supports strategies for prevention, diagnosis, and treatment by linking specific molecular or tissue changes with disease progression. Because tumor development connects molecular biology with tissue organization, findings can be interpreted at both the cellular and broader disease levels.